Liquidia Corp.

As of May 13, 2021, Liquidia Corp. is considered a risky investment due to its high Price to Book Value of 31.19, negative EV to EBIT and EV to EBITDA ratios, and a concerning Return on Equity of -271.66%, despite having previously shown strong long-term returns compared to the S&P 500.

As of October 13, 2023, Liquidia Corp. is rated "risky" and overvalued, with significant financial distress indicated by a negative ROE of -271.66%, a Price to Book Value of 31.19, and an unfavorable EV to EBITDA of -11.80, despite a year-to-date return of 12.76% that outperformed the S&P 500.

As of May 28, 2025, Liquidia Corp. shows a mildly bullish trend due to daily moving averages, but mixed signals from weekly indicators and recent underperformance against the S&P 500 suggest caution.

Liquidia Corp. is a late-stage clinical biopharmaceutical company focused on developing innovative products, with a market cap of approximately USD 1.16 billion. As of March 2025, it reported net sales of USD 3 million and a net loss of USD 38 million.

As of Jun 18, Liquidia Corp. has a market capitalization of 1,161.73 million, with net sales of 14.15 million and a net profit of -127.84 million over the latest four quarters. Shareholder's funds are at 77.28 million, and total assets amount to 233.17 million.